ESR1 and osteoporosis: Fifty-two of the eligible patients (56.5%) were treated for osteoporosis at least 3 months before surgery, including 24 with bone-forming agents, 21 with teriparatide, 3 with romosozumab, 15 with bisphosphonates, 8 with selective estrogen receptor modulators, and 5 with other agents.